How does ICU's Q3 2024 performance compare to Q4?

ICU's performance in Q3 2024 was significantly worse than in Q4 2024, with a revenue decline and a much larger net loss.

1. **Revenue Decline**: The revenue for Q3 2024 was $135,000, while for Q4 2024, it was $68,000. This indicates a substantial decrease in revenue during the latter period.
2. **Increased Net Loss**: The net loss for Q3 2024 was $24.83 million, whereas for Q4 2024, it was $20.41 million. Although the net loss decreased, it was still larger in Q3, indicating a more severe financial situation in Q3 compared to Q4.
3. **Earnings Per Share (EPS) Difference**: The diluted EPS for Q3 2024 was -$6.63, while for Q4 2024, it was -$6.1. This suggests that the company's performance was worse in terms of earnings per share in Q3 2024.

In conclusion, ICU's Q3 2024 performance was notably worse than Q4 2024, with a revenue drop and a more substantial net loss.

|code|Ticker|Name|Date|Total Revenue (FY)|Net Income (FY)|Diluted EPS (FY)|market_code|
|---|---|---|---|---|---|---|---|
|ICU|ICU.O|SeaStar Medical|2023||-2.6232E7|-30.26|186|